阿伯西普联合以氟尿嘧啶为基础的化疗治疗晚期大肠癌的研究解析.ppt

读书报告 汇报人：罗娜 Background Patients with metastatic colorectal cancer (mCRC) previously-treated with oxaliplatin benefit significantly from the addition of aflibercept to FOLFIRI in relation to overall survival, progression-free survival and response rate. typically regimen Treatment of metastatic colorectal cancer (mCRC) typically involves a fluoropyrimidine-based hemotherapy regimen, combining infusional fluorouracil (5-FU) and leucovorin with oxaliplatin (FOLFOX regimen) or rinotecan (FOLFIRI regimen). FOLFOX+bevacizumab In the E3200 study, it was shown that the addition of bevacizumab to